Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Common Equity (2018 - 2025)

Historic Common Equity for Bio (TELA) over the last 8 years, with Q3 2025 value amounting to $1.6 million.

  • Bio's Common Equity rose 12482.46% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 12482.46%. This contributed to the annual value of $28.5 million for FY2024, which is 5072.29% up from last year.
  • As of Q3 2025, Bio's Common Equity stood at $1.6 million, which was up 12482.46% from $9.2 million recorded in Q2 2025.
  • Bio's Common Equity's 5-year high stood at $41.7 million during Q1 2021, with a 5-year trough of -$6.3 million in Q3 2024.
  • Moreover, its 5-year median value for Common Equity was $18.1 million (2025), whereas its average is $17.4 million.
  • In the last 5 years, Bio's Common Equity soared by 269435.8% in 2023 and then tumbled by 12052.89% in 2024.
  • Bio's Common Equity (Quarter) stood at $20.1 million in 2021, then fell by 28.82% to $14.3 million in 2022, then soared by 31.99% to $18.9 million in 2023, then surged by 50.72% to $28.5 million in 2024, then tumbled by 94.53% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $9.2 million for Q2 2025, and $18.1 million during Q1 2025.